Skip to content

Efficacy and Safety of Protein Product in Volunteers With Sarcopenia

Efficacy and Safety of Protein Product in Volunteers With Sarcopenia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05869305
Enrollment
45
Registered
2023-05-22
Start date
2023-06-01
Completion date
2024-03-20
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Brief summary

The objective of this study are to evaluate efficacy and safety of protein product in volunteers with sarcopenia.

Detailed description

There are 45 patients in this study. They are randomly divided into 3 groups which are whey protein isolate group, isolated soy protein group, placebo group. They will take the sample 1 sachet/day for 12 weeks. Muscle strength, muscle mass, physical performance, sarcopenia score, body weight, body mass index, protein, immunoglobulins, quality of life, liver function, kidney function, other laboratory value, and adverse effects are evaluated.

Interventions

DIETARY_SUPPLEMENTwhey protein isolate

Take 1 sachet/day for 12 weeks.

DIETARY_SUPPLEMENTisolated soy protein

Take 1 sachet/day for 12 weeks.

DIETARY_SUPPLEMENTplacebo

Take 1 sachet/day for 12 weeks.

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age more than 20 years * Sarcopenia score more than 4 * Handgrip strength less than 28 kg in male and less than 18 kg in female and muscle mass less than 7 kg/m2 in male and less than 5.7 kg/m2 in female or Gait speed (6-meter walk) less than 1 m/s * Can take protein from animal * Can read and write or have people to look after * Willing to participate in this study

Exclusion criteria

* Allergic to protein from animals and plants * Hepatitis or cirrhosis * Glomerular disease or glomerular filtration rate less than 60 ml/min/1.73m2 * Cancer or heart disease * Cannot walk * Pregnancy and lactation * Duodenal surgery * Take protein supplement within 2 weeks * Take protein in normal food more than 1.2 g/body weight/day * Participating in other studies

Design outcomes

Primary

MeasureTime frameDescription
Muscle strength12 weeksUsing handgrip strength instrument (high value means high strength)
Muscle mass12 weeksUsing Bioelectrical Impedance Analysis instrument (high value means high mass)
Physical performance12 weeksUsing Gait speed (6-meter walk) (low time period and low score of tired mean high physical performance.
Sarcopenia score12 weeksSarcopenia questionnaires (score 1 to 10 means low severity to high severity)
Body weight12 weeksBody weight of the patients
Body mass index12 weeksBody mass index of the patients

Secondary

MeasureTime frameDescription
Concentration of immunoglobulin in serum12 weeksMeasure concentration of immunoglobulin in serum
Concentration of glucose in serum12 weeksMeasure concentration of glucose in serum
Concentration of calcium in serum12 weeksMeasure concentration of calcium in serum
Concentration of magnesium in serum12 weeksMeasure concentration of magnesium in serum
Concentration of sodium in serum12 weeksMeasure concentration of sodium in serum
Concentration of aspartate transaminase in serum12 weeksMeasure concentration of aspartate transaminase in serum
Concentration of alanine aminotransferase in serum12 weeksMeasure concentration of alanine aminotransferase in serum
Concentration of alkaline phosphatase in serum12 weeksMeasure concentration of alkaline phosphatase in serum
Skin reaction12 weeksFound or not found
Respiratory reaction12 weeksFound or not found
Gastrointestinal tract reaction12 weeksFound or not found
Concentration of creatinine in serum12 weeksMeasure concentration of creatinine in serum
Concentration of blood urea nitrogen in serum12 weeksMeasure concentration of blood urea nitrogen in serum
Nutritional status12 weeksNutritional score (score 0 to 17 means lack of nutrition, score 17 to 23.5 means risk to have lack of nutrition, score 24 to 30 means normal nutrition)
Hungry feeling12 weeksUsing visual analogue scale 0 to 10 (No hungry to very hungry)
Quality of life of the patient12 weeks36-Item Short Form Survey questionnaires shows in quality of life score 0 to 100 (High score means a better outcome)
Concentration of total protein in serum12 weeksMeasure concentration of total protein in serum

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026